General Information of Drug Therapeutic Target (DTT) (ID: TTZ4JC3)

DTT Name Neutrophil cytosol factor 1 (NCF1)
Synonyms
SH3PXD1A; SH3 and PX domain-containing protein 1A; P47-phox; P47(phox) NAD(P)H oxidase; Nox-organizing protein 2; Nox organizer 2; Neutrophil NADPH oxidase factor 1; NOXO2; NCF-47K; NCF-1; 47 kDa neutrophil oxidase factor; 47 kDa autosomal chronic granulomatous disease protein
Gene Name NCF1
DTT Type
Literature-reported target
[1]
UniProt ID
NCF1_HUMAN
TTD ID
T47492
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MGDTFIRHIALLGFEKRFVPSQHYVYMFLVKWQDLSEKVVYRRFTEIYEFHKTLKEMFPI
EAGAINPENRIIPHLPAPKWFDGQRAAENRQGTLTEYCSTLMSLPTKISRCPHLLDFFKV
RPDDLKLPTDNQTKKPETYLMPKDGKSTATDITGPIILQTYRAIANYEKTSGSEMALSTG
DVVEVVEKSESGWWFCQMKAKRGWIPASFLEPLDSPDETEDPEPNYAGEPYVAIKAYTAV
EGDEVSLLEGEAVEVIHKLLDGWWVIRKDDVTGYFPSMYLQKSGQDVSQAQRQIKRGAPP
RRSSIRNAHSIHQRSRKRLSQDAYRRNSVRFLQQRRRQARPGPQSPGSPLEEERQTQRSK
PQPAVPPRPSADLILNRCSESTKRKLASAV
Function NCF2, NCF1, and a membrane bound cytochrome b558 are required for activation of the latent NADPH oxidase (necessary for superoxide production).
KEGG Pathway
Chemokine signaling pathway (hsa04062 )
Phagosome (hsa04145 )
Osteoclast differentiation (hsa04380 )
Neutrophil extracellular trap formation (hsa04613 )
Fc gamma R-mediated phagocytosis (hsa04666 )
Leukocyte transendothelial migration (hsa04670 )
Prion disease (hsa05020 )
Leishmaniasis (hsa05140 )
Chemical carcinogenesis - reactive oxygen species (hsa05208 )
Diabetic cardiomyopathy (hsa05415 )
Lipid and atherosclerosis (hsa05417 )
Fluid shear stress and atherosclerosis (hsa05418 )
Reactome Pathway
Cross-presentation of particulate exogenous antigens (phagosomes) (R-HSA-1236973 )
Detoxification of Reactive Oxygen Species (R-HSA-3299685 )
VEGFA-VEGFR2 Pathway (R-HSA-4420097 )
RHO GTPases Activate NADPH Oxidases (R-HSA-5668599 )
RAC1 GTPase cycle (R-HSA-9013149 )
RAC2 GTPase cycle (R-HSA-9013404 )
RAC3 GTPase cycle (R-HSA-9013423 )
ROS and RNS production in phagocytes (R-HSA-1222556 )

References

1 The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci. 2003 Sep;24(9):471-8.